Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Alto Neuroscience Over Alleged Misleading Statements

Strategic Insights

— 2 min read

A class action lawsuit has been filed in the United States District Court for the Northern District of California against Alto Neuroscience, Inc. and certain officers on behalf of investors who purchased or acquired the company's common stock during an initial public offering (IPO) in February 2024 and up to October 2024. The lawsuit alleges that the defendants made false and misleading statements regarding the effectiveness of the company's drug candidate, ALTO-100, in treating major depressive disorder (MDD).

The lawsuit claims that the defendants' statements in the IPO documents and subsequent press releases were untrue and omitted material facts, leading to an overstatement of the company's clinical, regulatory, and commercial prospects. On October 22, 2024, Alto announced topline results from a Phase 2b trial evaluating ALTO-100 for MDD, which showed that the drug did not meet its primary endpoint, causing the company's stock price to plummet. The lawsuit seeks damages on behalf of investors who purchased Alto securities during the alleged class period.

Key Takeaways:

  • The lawsuit alleges that Alto's IPO documents and press releases contained untrue statements of material fact and omitted necessary information, leading to an overstatement of the company's prospects.
  • The lawsuit claims that Alto's drug candidate, ALTO-100, was less effective in treating MDD than defendants had led investors to believe.
  • The lawsuit seeks damages on behalf of investors who purchased Alto securities during the alleged class period.
  • The class period spans from February 2, 2024, to October 22, 2024, and includes all investors who purchased or acquired Alto common stock during this time.
  • The lawsuit was filed in the United States District Court for the Northern District of California on August 25, 2025.

Statistics:

  • Alto's stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
  • The company's common stock continues to trade below the $16.00 per share IPO price, causing damages to investors.
  • The lawsuit seeks to recover damages on behalf of investors who purchased Alto securities during the alleged class period.

Sources:

  • Pomerantz LLP's press release dated August 25, 2025
  • The United States District Court for the Northern District of California's docket 25-cv-06105
  • Alto Neuroscience's IPO documents, including the Registration Statement and Prospectus, filed with the Securities and Exchange Commission on February 1, 2024
  • Alto's press release announcing topline results from the Phase 2b trial evaluating ALTO-100 for MDD, dated October 22, 2024

Read more